Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Evolving Industry Trends and key Insights by 2026

Methicillin-Resistant Staphylococcus Aureus
(MRSA) Drugs Market Evolving Industry Trends
and key Insights by 2026
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drugs
(Zyvox, Cubicin, Sivextro, Daptomycin, Tygacil, Teflaro, and Others), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) and By Geography - Global Industry Insights, Trends, Outlook and
Opportunity Analysis 2018-2026
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which
became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used
antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the
world population, which comprises around 33%, as per Centers for Disease Control and Prevention
(CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital
Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA).
Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain
life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection),
osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic
bursitis (formation of small fluid-filled sacs under the skin). Growth of the methicillin-resistant
staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing
adoption of organic and inorganic strategies by key market players. Click To Read More On
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market.
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus
aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus
(MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc.,
received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as
well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new
route of administration are experimented by market players to treat MRSA infection. For instance, in
2018, Destiny Pharma received investigational new drug application from FDA for its new candidate,
XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of
methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is
expected to aid in growth of the MRSA drugs market over the forecast period.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1538
Moreover, funding programs by healthcare organization will also propel drug discovery and
development program, in turn leading to growth of the MRSA drug market. For instance, in 2017,
Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of
Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty
pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation
powder, intended to treat MRSA lung infection in individual with cystic fibrosis.
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor
Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea
Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma,
Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King
Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market
are focusing inorganic growth strategies in order to enhance its market share and remain competitive in
the market.
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Regional Analysis
Geographically, global methicillin-resistant staphylococcus aureus (MRSA) drugs market is segmented
into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America
holds dominant position in methicillin-resistant staphylococcus aureus (MRSA) drugs market, owing to
increasing research and development studies by key market players to come up with new drug. For
instance, in 2016, Allergan plc received US FDA approval for Dalance in injectable form for acute
bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus
aureus (MRSA). Asia Pacific is expected to witness fastest growth over the forecast period. This is due
to larger patient pool and increasing market player’s strategies to expand their geographical reach in
this region.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics.

Download Report